- Home
- SLS vs RNAC Comparison
SLS vs RNAC Comparison
Compare SLS & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | RNAC |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.0M | 177.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SLS | RNAC |
|---|---|---|
| Price | $3.51 | $6.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $38.80 |
| AVG Volume (30 Days) | ★ 8.3M | 114.7K |
| Earning Date | 03-19-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,091,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $5.98 |
| 52 Week High | $5.18 | $20.00 |
Technical Indicators
Market Signals| Indicator | SLS | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 35.63 |
| Support Level | $3.66 | $6.74 |
| Resistance Level | $4.20 | $7.28 |
| Average True Range (ATR) | 0.42 | 0.44 |
| MACD | -0.14 | -0.10 |
| Stochastic Oscillator | 1.48 | 2.21 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.